and a 36-month beta value of 0.83. Opinions on the stock are mixed, with 10 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”

The average price predicted for Sutro Biopharma Inc (STRO) by analysts is $15.80, which is $13.11 above the current market price. The public float for STRO is 57.73M, and at present, short sellers hold a 4.10% of that float. On November 20, 2023, the average trading volume of STRO was 513.47K shares.

STRO) stock’s latest price update

The stock price of Sutro Biopharma Inc (NASDAQ: STRO) has surged by 14.47 when compared to previous closing price of 2.35, but the company has seen a 29.33% gain in its stock price over the last five trading sessions. Zacks Investment Research reported 2023-11-13 that Sutro Biopharma (STRO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

STRO’s Market Performance

STRO’s stock has risen by 29.33% in the past week, with a monthly drop of -18.24% and a quarterly drop of -41.90%. The volatility ratio for the week is 13.21% while the volatility levels for the last 30 days are 10.11% for Sutro Biopharma Inc The simple moving average for the last 20 days is 3.90% for STRO stock, with a simple moving average of -41.40% for the last 200 days.

Analysts’ Opinion of STRO

Many brokerage firms have already submitted their reports for STRO stocks, with Deutsche Bank repeating the rating for STRO by listing it as a “Buy.” The predicted price for STRO in the upcoming period, according to Deutsche Bank is $12 based on the research report published on November 09, 2023 of the current year 2023.

STRO Trading at -17.75% from the 50-Day Moving Average

After a stumble in the market that brought STRO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -69.15% of loss for the given period.

Volatility was left at 10.11%, however, over the last 30 days, the volatility rate increased by 13.21%, as shares sank -15.67% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -40.49% lower at present.

During the last 5 trading sessions, STRO rose by +29.33%, which changed the moving average for the period of 200-days by -63.40% in comparison to the 20-day moving average, which settled at $2.56. In addition, Sutro Biopharma Inc saw -66.71% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at STRO starting from Shtylla Brunilda, who sale 15,428 shares at the price of $4.71 back on Aug 28. After this action, Shtylla Brunilda now owns 0 shares of Sutro Biopharma Inc, valued at $72,595 using the latest closing price.

Shtylla Brunilda, the Chief Business Officer of Sutro Biopharma Inc, sale 11,613 shares at $4.59 during a trade that took place back on Aug 25, which means that Shtylla Brunilda is holding 12,928 shares at $53,282 based on the most recent closing price.

Stock Fundamentals for STRO

Current profitability levels for the company are sitting at:

The net margin for Sutro Biopharma Inc stands at -175.89. The total capital return value is set at -44.66, while invested capital returns managed to touch -43.35. Equity return is now at value -100.83, with -41.43 for asset returns.

Based on Sutro Biopharma Inc (STRO), the company’s capital structure generated 23.23 points at debt to equity in total, while total debt to capital is 18.85. Total debt to assets is 12.39, with long-term debt to equity ratio resting at 15.36. Finally, the long-term debt to capital ratio is 12.47.

When we switch over and look at the enterprise to sales, we see a ratio of -2.47, with the company’s debt to enterprise value settled at 0.40. The receivables turnover for the company is 6.92 and the total asset turnover is 0.18. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.31.


To sum up, Sutro Biopharma Inc (STRO) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.